Caseware UK (AP4) 2022.0.179 2022.0.179 2023-07-312023-07-31falsetrueNo description of principal activity2022-08-0122trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 07635513 2022-08-01 2023-07-31 07635513 2021-08-01 2022-07-31 07635513 2023-07-31 07635513 2022-07-31 07635513 c:Director1 2022-08-01 2023-07-31 07635513 d:CurrentFinancialInstruments 2023-07-31 07635513 d:CurrentFinancialInstruments 2022-07-31 07635513 d:CurrentFinancialInstruments d:WithinOneYear 2023-07-31 07635513 d:CurrentFinancialInstruments d:WithinOneYear 2022-07-31 07635513 d:ShareCapital 2023-07-31 07635513 d:ShareCapital 2022-07-31 07635513 d:RetainedEarningsAccumulatedLosses 2023-07-31 07635513 d:RetainedEarningsAccumulatedLosses 2022-07-31 07635513 c:FRS102 2022-08-01 2023-07-31 07635513 c:AuditExempt-NoAccountantsReport 2022-08-01 2023-07-31 07635513 c:FullAccounts 2022-08-01 2023-07-31 07635513 c:PrivateLimitedCompanyLtd 2022-08-01 2023-07-31 07635513 6 2022-08-01 2023-07-31 iso4217:GBP xbrli:pure

Registered number: 07635513









A&D PHARMACHEM LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 JULY 2023

 
A&D PHARMACHEM LIMITED
REGISTERED NUMBER: 07635513

BALANCE SHEET
AS AT 31 JULY 2023

2023
2022
Note
£
£

Fixed assets
  

Investments
 4 
1,056,281
1,056,281

  
1,056,281
1,056,281

Current assets
  

Cash at bank and in hand
 5 
182
423

  
182
423

Creditors: amounts falling due within one year
 6 
(688,670)
(610,638)

Net current liabilities
  
 
 
(688,488)
 
 
(610,215)

Total assets less current liabilities
  
367,793
446,066

  

Net assets
  
367,793
446,066


Capital and reserves
  

Called up share capital 
  
1
1

Profit and loss account
  
367,792
446,065

  
367,793
446,066


Page 1

 
A&D PHARMACHEM LIMITED
REGISTERED NUMBER: 07635513
    
BALANCE SHEET (CONTINUED)
AS AT 31 JULY 2023

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
Mr A S Shah
Director

Date: 11 April 2024

The notes on pages 3 to 5 form part of these financial statements.

Page 2

 
A&D PHARMACHEM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

1.


General information

A&D Pharmachem Limited is a private company limited by shares. The company is incorporated in England and the address of its registered office is 174 Broadfields Avenue, Edgware, Middlesex, HA8 8TF. The registered number is 07635513. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current corporation tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the United Kingdom where the Company operates and generates income.

Page 3

 
A&D PHARMACHEM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

2.Accounting policies (continued)

 
2.4

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of income and retained earnings for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.7

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.


3.


Employees

The average monthly number of employees, including directors, during the year was 2 (2022 - 2).


4.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


At 1 August 2022
1,056,281



At 31 July 2023
1,056,281




Page 4

 
A&D PHARMACHEM LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

5.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
182
423

182
423



6.


Creditors: Amounts falling due within one year

2023
2022
£
£

Corporation tax
12,033
12,336

Other creditors
676,637
598,302

688,670
610,638


 
Page 5